Mingjing Lin1, Shuxia Zhu2, Haimei Weng1, Yi Zhu3. 1. Department of Neonatal, Hainan General Hospital/Hainan Affiliated Hospital of Hainan Medical University Haikou 570311, Hainan Province, China. 2. Department of Paediatrics, Binzhou Medical University Hospital Binzhou 256600, Shandong Province, China. 3. Hospital Infection Management Office, The Hospital of Xinjiang Production and Construction Corps Urumqi 830002, Xinjiang Uygur Autonomous Region, China.
Abstract
OBJECTIVE: To explore the effect of cefoperazone sulbactam sodium combined with meropenem on the immune function in the treatment of neonatal multi-drug resistant pneumonia. METHODS: Altogether 130 children with pneumonia caused by multi-drug resistant bacteria admitted to our hospital from January 2016 to January 2019 were recruited as the study cohort. The children were randomly divided into a combined group (n=80, combined therapy) and a control group (n=50, cefoperazone sulbactam sodium therapy). Their clinical indexes and their pulmonary function indexes, their serum heparin-binding protein (HBP) 1,25-dihydroxy vitamin D3 [1,25-(OH)2D3] levels, and their inflammatory factors and immune indexes were observed. The bacterial eradication rates, total effective rates, and adverse reaction rates of the two groups were investigated. RESULTS: Compared with the control group, the cough disappearance times, the antipyretic times, the pulmonary rales disappearance times, and the hospital stay lengths in the combination group were shorter, the FEV1% Pred (the percentage of forced expiratory volume in one second compared to the predicted value) and the FEV1/Fvc% (the percentage of forced expiratory volume in one second compared to the forced vital capacity) were higher, the HBP levels and the inflammatory factor CRP and IL-6 levels were lower, the 1,25-(OH)2D3, and the immune index gA, IgG, and C4 levels were higher, and the bacterial eradication rates and the total effective rates were higher, and the incidence of adverse reactions was lower. CONCLUSION:Cefoperazone sulbactam sodium combined with meropenem can improve the immune function of newborn children with multi-drug resistant pneumonia. AJTR
RCT Entities:
OBJECTIVE: To explore the effect of cefoperazone sulbactam sodium combined with meropenem on the immune function in the treatment of neonatal multi-drug resistant pneumonia. METHODS: Altogether 130 children with pneumonia caused by multi-drug resistant bacteria admitted to our hospital from January 2016 to January 2019 were recruited as the study cohort. The children were randomly divided into a combined group (n=80, combined therapy) and a control group (n=50, cefoperazone sulbactam sodium therapy). Their clinical indexes and their pulmonary function indexes, their serum heparin-binding protein (HBP) 1,25-dihydroxy vitamin D3 [1,25-(OH)2D3] levels, and their inflammatory factors and immune indexes were observed. The bacterial eradication rates, total effective rates, and adverse reaction rates of the two groups were investigated. RESULTS: Compared with the control group, the cough disappearance times, the antipyretic times, the pulmonary rales disappearance times, and the hospital stay lengths in the combination group were shorter, the FEV1% Pred (the percentage of forced expiratory volume in one second compared to the predicted value) and the FEV1/Fvc% (the percentage of forced expiratory volume in one second compared to the forced vital capacity) were higher, the HBP levels and the inflammatory factor CRP and IL-6 levels were lower, the 1,25-(OH)2D3, and the immune index gA, IgG, and C4 levels were higher, and the bacterial eradication rates and the total effective rates were higher, and the incidence of adverse reactions was lower. CONCLUSION:Cefoperazone sulbactam sodium combined with meropenem can improve the immune function of newborn children with multi-drug resistant pneumonia. AJTR
Authors: Rajnikant Sharma; Saloni Patel; Cely Abboud; John Diep; Neang S Ly; Jason M Pogue; Keith S Kaye; Jian Li; Gauri G Rao Journal: Int J Antimicrob Agents Date: 2016-12-23 Impact factor: 5.283
Authors: George G Zhanel; Courtney K Lawrence; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Michael Zhanel; Philippe R S Lagacé-Wiens; Andrew Walkty; Andrew Denisuik; Alyssa Golden; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky Journal: Drugs Date: 2018-01 Impact factor: 9.546
Authors: Patrícia Mouta Nunes de Oliveira; Sibelle Nogueira Buonora; Cristina Letícia Passos Souza; Robinson Simões Júnior; Thais Carolina da Silva; Gabriel José Teixeira Bom; Caio Henrique da Silva Teixeira; André Ricardo Araujo da Silva Journal: Rev Soc Bras Med Trop Date: 2019-09-05 Impact factor: 1.581
Authors: Francesco Violi; Roberto Cangemi; Marco Falcone; Gloria Taliani; Filippo Pieralli; Vieri Vannucchi; Carlo Nozzoli; Mario Venditti; Julio A Chirinos; Vicente F Corrales-Medina Journal: Clin Infect Dis Date: 2017-06-01 Impact factor: 9.079
Authors: Neha M Doshi; Charles H Cook; Kari L Mount; Stanislaw P Stawicki; Erin N Frazee; Heather A Personett; Garrett E Schramm; Heather M Arnold; Claire V Murphy Journal: BMC Anesthesiol Date: 2013-11-25 Impact factor: 2.217